Manic depression medication list

A manic depression medication list is a structured clinical reference to the drugs prescribed for bipolar disorder, organized by class, FDA indication, and episode phase. Four classes do the work: mood stabilizers, atypical antipsychotics, anticonvulsants, and antidepressants used only as add-on cover.

Lithium remains the first-line agent for acute mania and for maintenance. Lamotrigine holds bipolar I maintenance, lurasidone and lumateperone treat bipolar depression, and quetiapine covers all three phases. No antidepressant is approved to run alone.

Bipolar disorder, historically called manic depression, affects 1-3% of the population and needs long-term medication management. This guide sets out every FDA-approved option by class and phase, the monitoring each one commits you to, and a downloadable PDF for your practice.

Key takeaways

Mood stabilizers such as lithium, valproate, lamotrigine and carbamazepine carry bipolar maintenance, with the choice set by episode phase and comorbidities.

Atypical antipsychotics including quetiapine, olanzapine, aripiprazole, lurasidone and cariprazine are approved for acute episodes, and each one needs metabolic monitoring.

Antidepressants are never monotherapy in bipolar disorder, because they can trigger mania; they run only alongside a mood stabilizer or antipsychotic.

A structured medication list built on digital intake forms and AI-powered clinical documentation keeps tracking consistent across episodes.

What manic depression means today

Manic depression is the historical term for bipolar disorder, a mood disorder marked by alternating episodes of mania (or hypomania in bipolar II) and depression. The older name still appears in patient conversation and in pre-1990s literature. “Bipolar disorder” is the standard clinical nomenclature.

Bipolar I involves full manic episodes: high energy, decreased need for sleep, impulsivity, and risk-taking. Bipolar II involves hypomanic episodes, a milder mood elevation, combined with depressive episodes. Each subtype calls for a different medication strategy in acute and maintenance phases.

• Bipolar I: Acute mania, acute depression, maintenance (cycling or stable)
• Bipolar II: Hypomanic episodes, major depressive episodes, maintenance
• Rapid cycling: Four or more mood episodes per year; affects ~10-20% of bipolar patients and calls for adjusted medication protocols

The table below organizes FDA-approved bipolar medications by class and indication. All entries reflect current labeling as of 2026. Verify current prescribing information with the FDA or your national regulatory body before you prescribe.

This table reflects FDA-approved indications documented in peer-reviewed literature. Topiramate and oxcarbazepine are used off-label. Weigh the risk and the benefit against your own regulatory body’s guidance before you prescribe either.

Mood stabilizers for bipolar disorder

Mood stabilizers are the foundational class for bipolar treatment, with lithium as the gold standard. They are used mainly for maintenance and to prevent relapse.

• Lithium carbonate: Gold-standard mood stabilizer approved for acute mania and maintenance. A narrow therapeutic index (0.6-1.2 mEq/L) means regular serum levels, renal function checks, and thyroid surveillance
• Valproate (Depakote): FDA-approved for acute mania, and effective in rapid-cycling bipolar and acute agitation. A boxed warning for teratogenicity (neural tube defects) applies, so contraception counseling is advised for women of reproductive age
• Lamotrigine (Lamictal): FDA-approved for bipolar I maintenance; particularly useful where depressive episodes dominate; slow titration avoids rash (Stevens-Johnson syndrome risk ~0.3%); ineffective in acute mania
• Carbamazepine (Tegretol, Equetro): FDA-approved for acute mania; an anticonvulsant with complex drug interactions (strong CYP3A4 inducer); needs baseline CBC and liver and kidney function monitoring

Prescribing practice varies by region. National guidance such as NICE CG185 sets out first-line agent selection and monitoring frequency in more detail than a product label does.

Atypical antipsychotics for bipolar disorder

Second-generation (atypical) antipsychotics now sit alongside mood stabilizers in acute and maintenance treatment. FDA-approved agents span acute mania, acute depression, and maintenance, with side-effect profiles that differ sharply between them.

• Quetiapine (Seroquel): Broad FDA approval covering acute mania, acute depression, and maintenance; widely prescribed; sedating, with significant weight gain and metabolic risk
• Olanzapine (Zyprexa): FDA-approved for acute mania and maintenance; highest metabolic and weight-gain risk of the class; effective in treatment-resistant cases; needs stringent metabolic monitoring
• Aripiprazole (Abilify): Approved for acute mania and maintenance; lower metabolic burden than quetiapine or olanzapine; movement-disorder risk (akathisia); available in long-acting formulations
• Lurasidone (Latuda): FDA-approved specifically for bipolar depression, not mania; weight-neutral; must be taken with food (≥350 kcal) for absorption; prolactin elevation risk
• Cariprazine (Vraylar): Approved for acute mania and acute depression. Terminal half-life is roughly 2-4 days, and an active metabolite persists for one to three weeks. Movement-disorder monitoring needed
• Lumateperone (Caplyta): Newer agent approved for bipolar depression; weight-neutral; minimal metabolic side effects; worth considering in metabolically vulnerable patients

Atypical antipsychotics are often paired with a mood stabilizer during an acute episode, then tapered or continued through maintenance depending on response.

Anticonvulsants used in bipolar disorder

Anticonvulsants overlap with mood stabilizers in both mechanism and clinical use. Lamotrigine and carbamazepine hold FDA approval. Topiramate, oxcarbazepine, and levetiracetam are used off-label.

• Lamotrigine & carbamazepine: See the mood stabilizers section above, where the FDA approvals and monitoring profiles are set out
• Topiramate: Off-label use in bipolar mania and rapid cycling; weight-neutral, with weight loss possible; cognitive effects reported; no FDA approval for a bipolar indication
• Oxcarbazepine: Off-label mood stabilizer; fewer drug interactions than carbamazepine; hyponatremia risk with long-term use

Off-label anticonvulsant use needs a documented clinical rationale and the patient’s consent. Your prescription management software should flag an off-label indication at the moment of prescribing, not at audit.

Antidepressants in bipolar disorder: Use with caution

Antidepressants (SSRIs, SNRIs, tricyclics) are used in bipolar depression, but they can trigger mania or rapid cycling. None of them should be prescribed as monotherapy.

• FDA guidance: No antidepressant is FDA-approved as monotherapy for bipolar depression; every antidepressant needs concurrent mood stabilizer or antipsychotic cover
• SSRI choice: SSRIs (sertraline, paroxetine, fluoxetine) are preferred over tricyclics or SNRIs because mania-induction risk is lower, though it is never zero
• Monitoring: After starting an antidepressant, watch closely for mood destabilization through weeks 1-12; reduce the dose or stop if mania emerges
• Maintenance: Antidepressants are often stopped once bipolar depression remits; long-term use in bipolar patients remains contested

Bipolar disorder medications by episode phase

Medication selection and dosing differ substantially by episode and by bipolar subtype. The table below maps evidence-based first-line choices across acute mania, acute depression, maintenance, and rapid cycling.

Phase transitions are worth documenting as they happen rather than reconstructing later. Psychiatry EMR software records which agent covered which episode, and a written bipolar treatment plan holds the first-line choice alongside the rationale for anything off-label.

Managing medication side effects

Tolerability drives adherence in bipolar medication management. Side effects vary by drug class and by individual patient factors.

• Weight gain and metabolic effects: Olanzapine and quetiapine carry the highest risk, while aripiprazole and lurasidone are weight-neutral. Check BMI, fasting glucose, and lipids every 3-6 months
• Lithium-specific: Tremor, polyuria, thyroid dysfunction, and renal impairment; baseline plus 6-12 monthly renal and thyroid function tests are mandatory; interacts with NSAIDs and ACE inhibitors
• Valproate (Depakote): Hepatotoxicity, pancreatitis, hair loss, and weight gain; baseline and annual liver function tests. A boxed warning for teratogenicity applies, so contraception counseling is advised
• Lamotrigine (Lamictal): Rash in roughly 10% of patients, occasionally severe (Stevens-Johnson syndrome, toxic epidermal necrolysis). The slow titration schedule is mandatory, and the patient is briefed to report any rash
• Antipsychotic movement disorders: Akathisia, tremor, and tardive dyskinesia over the long term. Score with a standardized tool such as the Abnormal Involuntary Movement Scale, then reduce the dose or switch agents if severe
• Prolactin elevation: A risk with risperidone, paliperidone, and amisulpride; causes sexual dysfunction and galactorrhea; lurasidone and aripiprazole have lower prolactin effects

Those intervals, not the drug classes above, are what set your recall calendar. Collected in one place, they show how far apart two patients on different agents need to be booked.

Screen for side effects at every visit rather than waiting for the patient to raise one. A structured psychiatric evaluation template puts the same prompts in front of you each time. That is what makes one visit’s record comparable with the last.

How Pabau supports bipolar medication management

Every bipolar patient on your list carries four moving records. The current episode phase, the agent covering it, the labs due next, and the side effects raised at the last visit. Paper notes and spreadsheets keep those four in four different places.

Practice management software like Pabau holds all four against one patient record. A lithium level due in six months becomes a scheduled recall instead of a note someone has to remember to act on. Therapy practice management software does the same job for counseling caseloads, where the review cycle is the appointment rather than a lab.

Pabau Scribe, our AI scribe, structures the medication review itself. Phase notation, dose changes, and monitoring flags land in the note without retyping. Start dates, dose adjustments, side-effect events, and lab schedules then sit in one searchable audit trail, which is what a regulator asks to see.

Simplify psychiatric medication tracking

Pabau schedules the recalls your monitoring intervals demand and keeps side-effect history against the patient record. Your whole bipolar caseload sits in one compliant audit trail.

Book a demo

Conclusion

Choosing the agent is the quick part of bipolar care. The monitoring that choice commits you to runs for years, and that is where a regimen quietly comes apart.

Two failures cause most of the trouble. A patient stops an agent because a side effect went unmentioned, or a due lab never got booked. Both are documentation problems before they become clinical ones.

Download the template to standardize how your practice records each agent, its phase, and its monitoring interval. Book a demo to see how Pabau turns those intervals into recalls that book themselves.

Continue your research

Need a structured psychiatric assessment? Psychiatric evaluation template gives you a framework for mental health history and baseline symptom documentation before medication starts.

Writing the plan behind the prescription? Bipolar treatment plan sets out goals, interventions, and review points so the rationale for each agent is on the record.

Tracking mood between appointments? Daily mood chart gives patients a simple log that turns into usable evidence at the next medication review.

Scoring a manic episode? Young Mania Rating Scale (YMRS) template scores severity consistently, so dose decisions rest on a number rather than an impression.

Frequently asked questions